Back to search results

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

Abroad (travel likely)RecruitingPHASE1

Conditions

Gastric Adenocarcinoma · Gastroesophageal Junction (GEJ) Adenocarcinoma · Pancreatic Adenocarcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • University of California Irvine Medical Center, Orange, California, United States

  • UCLA Dept of Medicine - Hematology/Oncology, Santa Monica, Santa Monica, California, United States

  • Northwestern University, Chicago, Illinois, United States

  • University of Kansas Cancer Center, Westwood, Kansas, United States

  • Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

  • NYU Langone Medical Center - NYU Medical Oncology Associates, New York, New York, United States

  • Columbia University, New York, New York, United States

  • Memorial Sloan Kettering Cancer Center, New York, New York, United States

  • Duke Children's Hospital and Health Center, Durham, North Carolina, United States

  • Wake Forest University Baptist Health, Winston-Salem, North Carolina, United States

  • UT Southwestern Medical Center, Dallas, Texas, United States

  • Virginia Mason Medical Center, Seattle, Washington, United States

  • Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States

  • Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

  • Henan Cancer Hospital, Zhengzhou, Henan, China

  • Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China

  • Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai Municipality, China

  • The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

  • Site FR33005, Vaillant, Villejuif, France

  • Site FR33003, Lyon, France

  • Site FR33004, Marseille, France

  • Site FR33006, Poitiers, France

  • Site FR33001, Saint-Herblain, France

  • Site FR33002, Toulouse, France

  • Site IT39004, Milan, Italy

  • Site IT39001, Milan, Italy

  • Site IT39005, Rozzano, Italy

  • Site IT39003, Verona, Italy

  • Aichi Cancer Center, Nagoya, Aichi-ken, Japan

  • National Cancer Center Hospital East, Kashiwa, Chiba, Japan

  • Kanagawa Cancer Center, Yokohama, Kanagawa, Japan

  • Kindai University Hospital, Sakai, Osaka, Japan

  • The University of Osaka Hospital, Suita, Osaka, Japan

  • National Cancer Center Hospital, Chuo-ku, Tokyo, Japan

  • The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan

  • PanOncology Trials, San Juan, Puerto Rico

  • Site KR82004, Seongnam-si, Gyeonggi-do, South Korea

  • Site KR82001, Guro-gu, Seoul, South Korea

  • Site KR82002, Jongno-gu, Seoul, South Korea

  • Site KR82003, Seocho-gu, Seoul, South Korea

  • Site KR82005, Seodaemun-gu, Seoul, South Korea

  • Site ES34001, Barcelona, Spain

  • Site ES34002, Barcelona, Spain

  • Site ES34006, Barcelona, Spain

  • Site ES34007, El Palmar, Spain

  • Site ES34004, Zaragoza, Spain

Study leads

  • Senior Director

    Study Director

    Astellas Pharma Global Development, Inc.

View source on ClinicalTrials.gov(opens in a new tab)